Annual report
Awaiting price reaction for this filing.
Dolphin Medical Services Ltd submitted its 33rd Annual Report for FY 2024-25 to BSE, covering the year ended March 31, 2025. The company reported a total income of Rs. 77.95 lakh (up from Rs. 67.86 lakh in FY24) but continued to make a loss, with a loss after tax of Rs. 3.38 lakh, though this was an improvement from the Rs. 10.40 lakh loss in the previous year. No dividend was declared, there were no changes to the business or board, and the company has no subsidiaries or associates. The 33rd AGM is scheduled for September 29, 2025 in Hyderabad, with agenda items including adoption of financial statements, reappointment of a retiring director, and appointment of M/s. Kota & Associates as statutory auditors for a five-year term.
The narrower annual loss is a positive sign showing improved operational performance, but the company remains in the red with no dividend for shareholders. With a small revenue base and continued losses, investors should view this small-cap pharma company cautiously as near-term profitability recovery is still uncertain.